Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma ...

Daratumumab is a human IgGκ monoclonal antibody that targets CD38, which is highly expressed on myeloma cells and other hematopoietic cell types. 5,6 Daratumumab has direct and indirect antitumor ...

How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti-multiple myeloma (MM ...

The committee concluded that daratumumab is well tolerated, improves quality of life for people who take it, and allows them to receive other treatments further down the pathway. The company's model ...

RIO DE JANEIRO — The addition of daratumumab to lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly improves rates of achieving minimal residual ...

CHICAGO — The addition of daratumumab to chemotherapy improved outcomes among younger patients with relapsed or refractory T-cell acute lymphoblastic leukemia, study results showed. Perspective ...

Daratumumab significantly reduced progression risk in smoldering multiple myeloma, especially in high-risk patients, with a 64% reduction compared to active monitoring. The treatment did not ...

SAN DIEGO — In the MAIA study, adding the monoclonal antibody daratumumab (Darzalex, Janssen) to standard therapy significantly extended progression-free survival (PFS) in patients newly ...

Recent research on a treatment regimen comprising a daratumumab (Dara) backbone and an immumodulatory agent (IMiDs) demonstrates potential for this combination as a bridging therapy among patients ...

Please provide your email address to receive an email when new articles are posted on . Daratumumab delayed progression of smoldering multiple myeloma compared with active monitoring. Among those ...

Forest plots of daratumumab OS efficacy (vs. therapies without daratumumab) according to (A) low- and (B) high-physical function. The study analyzed data from 1,804 patients enrolled in three ...